Trial reportHypertension (Dallas, Tex. : 1979)2021
GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans.
Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Hypertension (Dallas, Tex. : 1979), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03486223 (Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans), which is not on this map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- On-DNA photochemical methods for expanding DNA-encoded library (DEL) chemical space.RSC medicinal chemistry · 2026Review
- Topliss-Guided Optimization of Acetanilide-Based Soluble Epoxide Hydrolase Inhibitors: Exploring the Pentafluorosulfanyl Group as a Potency-Enhancing Motif.ChemMedChem · 2026Article
- Fragment-Based Discovery of Fenamic Acids as Pan-Species Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.ACS chemical biology · 2026Article
- Lipid metabolism in homeostasis and disease.Signal transduction and targeted therapy · 2026Review
- Epoxy-oxylipins direct monocyte fate in inflammatory resolution in humans.Nature communications · 2026Article
- Soluble epoxide hydrolase inhibition restores pro-resolving lipid mediators and reduces inflammation in localized provoked vulvodynia.Frontiers in pharmacology · 2026Article
- Bioinformatics analyses of comorbid mechanisms between psoriasis and type 2 diabetes mellitus.Scientific reports · 2025Article
- Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease and Other Neurological Disorders: A Comprehensive Review.Biomedicines · 2025Review
- Intersecting Pathways of Inflammation, Oxidative Stress, and Atherogenesis in the Evaluation of CKD: Emerging Biomarkers PCSK9, EPHX2, AOPPs, and TBARSs.Life (Basel, Switzerland) · 2025Review
- Structure-Based Design of PROTACS for the Degradation of Soluble Epoxide Hydrolase.Journal of medicinal chemistry · 2025Article
- Article
- Structure-Based Design and Optimization Lead to the Identification of a Novel Potent sEH Inhibitor with PPARγ Partial Agonist Activity against Inflammatory and Metabolic-Related Diseases.Journal of medicinal chemistry · 2025Article
- Article
- Inhibition of Soluble Epoxide Hydrolase Ameliorates Cerebral Blood Flow Autoregulation and Cognition in Alzheimer's Disease and Diabetes-Related Dementia Rat Models.bioRxiv : the preprint server for biology · 2024Article
- Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy.Acta pharmaceutica Sinica. B · 2024Review
- Evolution of chemistry and selection technology for DNA-encoded library.Acta pharmaceutica Sinica. B · 2024Review
- Small-molecule discovery through DNA-encoded libraries.Nature reviews. Drug discovery · 2023Review
- Soluble epoxide hydrolase inhibitors for smoking-associated inflammatory lung diseases and chronic obstructive pulmonary disease: a meta-analytical systematic review of preclinical and clinical studies.American journal of translational research · 2023Review
- Designing a Small Fluorescent Inhibitor to Investigate Soluble Epoxide Hydrolase Engagement in Living Cells.ACS medicinal chemistry letters · 2022Article
- Soluble Epoxide Hydrolase and Diabetes Complications.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
James M LutherDepartment of Medicine, Division of Clinical Pharmacology (J.M.L., D.W., A.D., R.M., D.P., J.G., N.J.B.), Vanderbilt University Medical Center.ORCID 0000-0001-7225-2897
Justina RayDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY (J.R.).
Dawei WeiDepartment of Medicine, Division of Clinical Pharmacology (J.M.L., D.W., A.D., R.M., D.P., J.G., N.J.B.), Vanderbilt University Medical Center.
John R KoetheDepartment of Medicine, Division of Infectious Diseases (J.R.K., L.H.), Vanderbilt University Medical Center.
Latoya HannahDepartment of Medicine, Division of Infectious Diseases (J.R.K., L.H.), Vanderbilt University Medical Center.ORCID 0000-0002-1676-1096
Anthony DeMatteoDepartment of Medicine, Division of Clinical Pharmacology (J.M.L., D.W., A.D., R.M., D.P., J.G., N.J.B.), Vanderbilt University Medical Center.
Robert ManningDepartment of Medicine, Division of Clinical Pharmacology (J.M.L., D.W., A.D., R.M., D.P., J.G., N.J.B.), Vanderbilt University Medical Center.
Andrew S TerkerDepartment of Medicine, Division of Nephrology and Hypertension (A.S.T.), Vanderbilt University Medical Center.
Dungeng PengDepartment of Medicine, Division of Clinical Pharmacology (J.M.L., D.W., A.D., R.M., D.P., J.G., N.J.B.), Vanderbilt University Medical Center.
Hui NianDepartment of Biostatistics (H.N., C.Y.), Vanderbilt University Medical Center.
Chang YuDepartment of Biostatistics (H.N., C.Y.), Vanderbilt University Medical Center.
Mona MashayekhiDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism (M.M.), Vanderbilt University Medical Center.ORCID 0000-0003-0331-2395
Jorge GamboaDepartment of Medicine, Division of Clinical Pharmacology (J.M.L., D.W., A.D., R.M., D.P., J.G., N.J.B.), Vanderbilt University Medical Center.
Nancy J BrownDepartment of Medicine, Division of Clinical Pharmacology (J.M.L., D.W., A.D., R.M., D.P., J.G., N.J.B.), Vanderbilt University Medical Center.
Vanderbilt University Medical Center · USIcahn School of Medicine at Mount Sinai · USJohn Brown University · USVanderbilt University · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3MInstitutional Career Development CoreKL2TR002245 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Julie A. Bastarache · 2017 to 2026
$9.3MVanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DE CAESTECKER, MARK P. · 2017 to 2021
$5.9MVANDERBILT NEPHROLOGY TRAINING PROGRAMT32DK007569 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRIS, RAYMOND C., IKIZLER, TALAT ALP · 1988 to 2024
$5.8MVariation in Soluble Epoxide Hydrolase Activity and Human Insulin SensitivityR01DK117875 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BROWN, NANCY J., LUTHER, JAMES MATTHEW · 2018 to 2021
$1.9MBLRD VA I01 BX000320NCATS NIH HHS KL2 TR002245NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001863NCRR NIH HHS UL1 RR024975NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK114809NIDDK NIH HHS R01 DK117875NIDDK NIH HHS T32 DK007569
Abstract
[Figure: see text].
Indexed as
Insulin ResistanceAdipose TissueAdultCross-Over StudiesCyclohexylaminesDouble-Blind MethodEpoxide HydrolasesF2-IsoprostanesFemaleHumansMaleMiddle AgedMuscle, SkeletalTriazinesCyclohexylaminesEpoxide HydrolasesF2-IsoprostanesN-((4-cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamideTriazineseicosanoidsepoxide hydrolaseshypertensioninsulin resistanceoxidative stress
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03486223ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.